Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
January 2019
-
Media ReleaseSandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use DisorderreSET-O(TM)* is the first US FDA-cleared prescription digital therapeutic for patients with Opioid Use Disorder Cleared by the FDA in December, reSET-O is available immediately As part of a…
-
Flexibility at Novartis: Peter Canavan
Canavan describes how flexible working positively impacts his team.
-
Flexibility at Novartis: Deepti Mittal
Mittal shares how flexible working helped her and her family get through a difficult time.
December 2018
-
Key ReleaseNovartis successfully completes acquisition of EndocyteAdds 177Lu-PSMA-617, a potential first-in-class radioligand therapy in Phase III development for metastatic castration-resistant prostate cancer (mCRPC) Strengthens leadership in nuclear…
-
Media ReleaseNovartis receives European Commission (EC) approval for expanded indication for Kisqali® (ribociclib)Basel, December 21, 2018 - Novartis today announced that the European Commission (EC) approved an expanded indication for Kisqali® (ribociclib), the CDK4/6 inhibitor with the largest body of…
-
Media ReleaseNovartis announces offer to acquire CellforCure to expand manufacturing capacity for innovative cell and gene therapiesProposed acquisition builds on existing agreement with CellforCure for contract manufacturing of Novartis leading CAR-T cell therapy Kymriah® (tisagenlecleucel) and recent successful completion of…
-
Key ReleaseNovartis announces new CEO of Oncology Business UnitSusanne Schaffert, Ph.D., President, AAA, an established Novartis executive, named new CEO, Novartis Oncology Basel, December 20, 2018 - Novartis announced today that Susanne Schaffert, Ph.D.,…
-
Media ReleaseSandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden risesAgreement covers biosimilar insulins in early and clinical development for the top three selling branded insulins by sales: glargine, lispro and aspart Over 400 million people worldwide have…
-
Media ReleaseAlcon Announces Acquisition of Tear Film Innovations, Inc.Acquisition further expands Alcon's portfolio of comprehensive solutions for patients with dry eye Tear Film's iLux® Device offers innovative, customizable treatment for Meibomian Gland…
-
Media ReleaseNovartis receives European Commission approval for self-administration of Xolair® across all indicationsThe EC approval underscores the long-term safety and efficacy of Xolair demonstrated in clinical studies and by 13 years of real-world use in Europe[1] Xolair® (omalizumab) prefilled…
-
Women in Science: Susanne Schaffert
Susanne Schaffert, President of Advanced Accelerator Applications, describes her career in science.
-
Bringing real change to people
An interview with Thierry Diagana, Head of the Novartis Institute for Tropical Diseases.
Pagination
- ‹ Previous page
- 1
- …
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- …
- 152
- › Next page